TOTAL COMPANY

$9.7B
SALES WORLDWIDE

10% 1
Organic* sales growth for underlying base business**

$1.03 2
ADJUSTED DILUTED EPS

CONTINUE TO FORECAST

$4.30 to $4.50 3
FULL-YEAR 2023 ADJUSTED DILUTED EPS

Reflects increased outlook for underlying base business offset by lower forecasted earnings contribution from COVID-19 testing-related sales

BUSINESS HIGHLIGHTS

HELPING PEOPLE WITH DIABETES WHO USE INSULIN

- FDA clearance for FreeStyle Libre® 2 and FreeStyle Libre® 3 sensors for integration with automated insulin delivery (AID) systems
- AID systems automatically adjust and administer the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors

CARDIOVASCULAR LEADERSHIP

- New data show superiority of TriClip® device compared to medical therapy for tricuspid regurgitation, with significant improvement in quality of life
- Announced agreement to acquire Cardiovascular Systems, Inc. (CSI), which would add to our leading vascular device offerings

INNOVATION IN CHRONIC PAIN TREATMENT

- FDA approval of new indication for Proclaim® XR Spinal Cord Stimulation System to treat painful diabetic peripheral neuropathy
- System is able to use NeuroSphere™ Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely

BUSINESS UNIT SALES

$3.9B
MEDICAL DEVICES

$2.7B
DIAGNOSTICS

$1.2B
ESTABLISHED PHARMACEUTICALS

$2.0B
NUTRITION

*Organic sales growth excludes impact of foreign exchange, as well as the impact of exiting the pediatric nutrition business in China. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 19, 2023, available at www.abbottinvestor.com.
**Excludes the impact of COVID-19 testing sales.
***Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

†On a GAAP basis, first-quarter 2023 Abbott sales decreased 18.1%.
‡First-quarter GAAP diluted EPS was $0.75.
§Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to costs, including amortization, one-time impairment charges, and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.